Lightcalls.com
 

Huperzine A: protecting our brain, ...

Huperzine A: protecting our brain, individual neuron at a time.

The U Chamber of business estimates that every seven secondarys a Baby Boomer turns age 50 on these calculations, the new millennium will bring with it one 40 million Americans who will be candidates for the use of brain-boosting substances. take down huperzine A.

Nutritional support in the fight against Alzheimer's

In a consideration conducted at the Walter Re Army Institute of Research in Washington, DC it was freshly further validated that huperzine A (HupA) is an estimable pre-treatment, preventative agent and brain booster for Alzheimer's disease (AD), and the associated conditions of dementia.

First discovered as a part of the Chinese herbal medicine, Qian Ceng Ta, HupA is a natural compromise which has been shown to improve memory, enhance alertness, tend to the same point concentration, and focus thought processes

The standardized form of purified HupA, derived from the Chinese set moss, Huperzia serrata, has been laboratory criterioned and has demonstrated memory-enhancing activities in a broad range of animal and human brain-function models



Compared to existing prescription remedys HupA, as a nutritional fill up has better therapeutic indices for human patients, too, and its potential peripheral side forces are minimal at the therapeutic dose ranges (averaging 100 micrograms daily).

The Journal of the American Medical Association (JAMA) stated in its March 12 1997 issue that HupA-derived pharmaceuticals may become more effective therapeutic agents for AD than the brace drugs currently approved for use by the agency of the FDA: tacrine hydrochloride (TAC) and donepezil (Aricept). The existing Walter Reed Army Institute research confirms that HupA also compare notess more neuroprotection than the FDA remedys In addition, HupA has a longer-lasting duration of therapeutic effect

Physiological brain actions of HupA

It has been validated that HupA is a puissant blocker of the enzyme, acetylcholinesterase (ACHE), which breaks down acetylcholine, the neurotransmitter essential for memory and brain function. AChE inhibition be attendants to provide true brain-boosting by means of enhancing thinking and memory retention.

HupA exhibits novel "nerve protection" properties between the sides of its action at certain brain receptors. Also, it presents good penetration through the blood-brain barrier, high oral bioavailability, and longer duration of blocking action in succession AChE.

While FDA-approved cholinesterase inhibitors have been shown to be the effect in adverse effects -- of that kind as liver poisoning -- HupA has, thus far, shown no unexpect toxicity.

Researchers at the Walter Re Army Institute point without that HupA also decreases neuronal solitary abode; squalid death from stroke, epilepsy, and other brain disorders. It has been occupyed successfully in China for this view on at least 100,000 patients.

The scientist who first synthesized huperzine A standardized extract, Alan Kozikowski, PhD professor of pharmacy at Georgetown University's Institute of Cognitive and Computational Sciences in Washington, DC says HupA will be useful for anyone who wants to improve cognitive function and sharpen mental clarity, like as high-technology researchers, students, athletes, workers in states of stres overload, the somewhat old and Baby Boomers concerned about the aging process

REFERENCES

Doctor, BP "Age sustained by neuroprotective effect of huperzine A against excitatory amino acid toxicity," (In press) from the Divisions of Biochemistry and Neurosciences, Walter Re Army Institute of Research and the Georgetown University Medical Center (Washington, DC)

Gordon, RK Weitz, J.A., Dave, JR Doctor, BP V H "Huperzine A (Hup-A) interacts with the NMDA receptor ion channel," FASEB Journal 11:A903, 1997

Skolnick, A.A. "Old Chinese herbal medicine used for febrile affection yields possible new Alzheimer Disease therapy," JAMA 277(10):776 March 12 1997

V H Koenig, Mi., Dave, JR Doctor, BP "Huperzine A, a potential therapeutic agent for dementia, shortens neuronal cell death caused by the agency of glutamate," Neuro Report. 8:963-968, 1997

V H Nguyen T Kozikowski, A., Dave, J Gordon, RK Weitz, J.A., Dave, JR Doctor, BP V H "Hyperzine A (Hup-A) interacts with the NMDA receptor ion channel," FASEB Journal 11:A903, 1997

Dr Morton J Walker, a full-time, professional freelance medical journalist and author, has produc 73 published parts including Smart Nutrients, co-authored with Abram Hoffer MD PhD (Avery Publishing Group)

COPYRIGHT 1999 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved

COPYRIGHT 2000 Gale Group



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.